Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 94

1.

VEGF and MMP-9: biomarkers for canine lymphoma.

Aresu L, Aricò A, Comazzi S, Gelain ME, Riondato F, Mortarino M, Morello E, Stefanello D, Castagnaro M.

Vet Comp Oncol. 2014 Mar;12(1):29-36. doi: 10.1111/j.1476-5829.2012.00328.x. Epub 2012 Apr 10.

2.

The role of vascular endothelial growth factor and matrix metalloproteinases in canine lymphoma: in vivo and in vitro study.

Aricò A, Giantin M, Gelain ME, Riondato F, Comazzi S, Rütgen BC, Essler SE, Dacasto M, Castagnaro M, Aresu L.

BMC Vet Res. 2013 May 3;9:94. doi: 10.1186/1746-6148-9-94.

3.

Prognostic value of serum vascular endothelial growth factor (VEGF) and plasma activity of matrix metalloproteinase (MMP) 2 and 9 in lymphoma-affected dogs.

Gentilini F, Calzolari C, Turba ME, Agnoli C, Fava D, Forni M, Bergamini PF.

Leuk Res. 2005 Nov;29(11):1263-9.

PMID:
15893373
4.

Angiogenic markers in canine lymphoma tissues do not predict survival times in chemotherapy treated dogs.

Wolfesberger B, Tonar Z, Fuchs-Baumgartinger A, Walter I, Skalicky M, Witter K, Thalhammer JG, Pagitz M, Kleiter M.

Res Vet Sci. 2012 Jun;92(3):444-50. doi: 10.1016/j.rvsc.2011.04.018. Epub 2011 May 18.

PMID:
21596405
5.

Expression of matrix metalloproteinases, tissue inhibitors of metalloproteinases and vascular endothelial growth factor in canine mast cell tumours.

Giantin M, Aresu L, Benali S, Aricò A, Morello EM, Martano M, Vascellari M, Castagnaro M, Lopparelli RM, Zancanella V, Granato A, Mutinelli F, Dacasto M.

J Comp Pathol. 2012 Nov;147(4):419-29. doi: 10.1016/j.jcpa.2012.01.011. Epub 2012 Apr 19.

6.

Canine lymphomas: association of classification type, disease stage, tumor subtype, mitotic rate, and treatment with survival.

Valli VE, Kass PH, San Myint M, Scott F.

Vet Pathol. 2013 Sep;50(5):738-48. doi: 10.1177/0300985813478210. Epub 2013 Feb 26.

PMID:
23444036
7.

Matrix metalloproteinases and vascular endothelial growth factor expression in canine leukaemias.

Aricò A, Giantin M, Gelain M, Riondato F, Mortarino M, Comazzi S, Dacasto M, Castagnaro M, Aresu L.

Vet J. 2013 May;196(2):260-2. doi: 10.1016/j.tvjl.2012.10.004. Epub 2012 Nov 8.

8.
9.

Microvessel density in normal lymph nodes and lymphomas of dogs and their correlation with vascular endothelial growth factor expression.

Wolfesberger B, Tonar Z, Witter K, Guija de Arespacohaga A, Skalicky M, Walter I, Thalhammer JG, Egger GF.

Res Vet Sci. 2008 Aug;85(1):56-61. Epub 2007 Sep 20.

PMID:
17888471
11.

Role of Matrix Metalloproteinase-2, Matrix Metalloproteinase-9, and Vascular Endothelial Growth Factor in the Development of Chronic Subdural Hematoma.

Hua C, Zhao G, Feng Y, Yuan H, Song H, Bie L.

J Neurotrauma. 2016 Jan 1;33(1):65-70. doi: 10.1089/neu.2014.3724. Epub 2015 Aug 6.

12.

Expression levels of vascular endothelial growth factor, matrix metalloproteinases 2 and 9 and tissue inhibitor of metalloproteinases 1 and 2 in the plasma of patients with ovarian carcinoma.

Manenti L, Paganoni P, Floriani I, Landoni F, Torri V, Buda A, Taraboletti G, Labianca R, Belotti D, Giavazzi R.

Eur J Cancer. 2003 Sep;39(13):1948-56.

PMID:
12932675
13.

Expression of vascular endothelial growth factor and matrix metalloproteinase-9 in sacral chordoma.

Chen KW, Yang HL, Lu J, Wang GL, Ji YM, Wu GZ, Zhu LF, Liu JY, Chen XQ, Gu YP.

J Neurooncol. 2011 Feb;101(3):357-63. doi: 10.1007/s11060-010-0263-0. Epub 2010 Jun 15.

PMID:
20549300
14.

Relationship between serum levels of vascular endothelial growth factor, hepatocyte growth factor and matrix metalloproteinase-9 with biochemical markers of bone disease in multiple myeloma.

Alexandrakis MG, Sfiridaki A, Miyakis S, Pappa C, Kandidaki E, Alegakis A, Margioris AN.

Clin Chim Acta. 2007 Apr;379(1-2):31-5. Epub 2006 Dec 16.

PMID:
17234170
15.

Visfatin induces human endothelial VEGF and MMP-2/9 production via MAPK and PI3K/Akt signalling pathways: novel insights into visfatin-induced angiogenesis.

Adya R, Tan BK, Punn A, Chen J, Randeva HS.

Cardiovasc Res. 2008 May 1;78(2):356-65. Epub 2007 Dec 18.

PMID:
18093986
16.

MMP-2, MMP-9, VEGF and CA 15.3 in breast cancer.

Quaranta M, Daniele A, Coviello M, Venneri MT, Abbate I, Caringella ME, Di Tardo S, Divella R, Trerotoli P, Di Gennaro M, Schittulli F, Fransvea E, Giannelli G.

Anticancer Res. 2007 Sep-Oct;27(5B):3593-600.

17.

Levels of vascular endothelial growth factor and matrix metalloproteinase-9 proteins in patients with glioma.

Ma C, Li Y, Zhang X, Zhao G, Xu H.

J Int Med Res. 2014 Feb;42(1):198-204. doi: 10.1177/0300060513481924. Epub 2014 Jan 7.

PMID:
24398760
18.

Interleukin-6, vascular endothelial growth factor and transforming growth factor beta 1 in canine steroid responsive meningitis-arteritis.

Maiolini A, Otten M, Hewicker-Trautwein M, Carlson R, Tipold A.

BMC Vet Res. 2013 Feb 4;9:23. doi: 10.1186/1746-6148-9-23.

19.

The combination assay with circulating vascular endothelial growth factor (VEGF)-C, matrix metalloproteinase-9, and VEGF for diagnosing lymph node metastasis in patients with non-small cell lung cancer.

Tamura M, Oda M, Matsumoto I, Tsunezuka Y, Kawakami K, Ohta Y, Watanabe G.

Ann Surg Oncol. 2004 Oct;11(10):928-33. Epub 2004 Sep 20.

PMID:
15383417

Supplemental Content

Support Center